Genmab A/S (NASDAQ:GMAB) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Genmab A/S (NASDAQ:GMAB) have been given a consensus rating of “Moderate Buy” by the twelve analysts that are currently covering the stock, MarketBeat reports. Four investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $42.17.

GMAB has been the subject of a number of research analyst reports. Leerink Partners upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price objective for the company in a report on Thursday, February 13th. HC Wainwright reiterated a “buy” rating and issued a $50.00 target price on shares of Genmab A/S in a research note on Thursday, January 23rd. BNP Paribas upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 11th. BMO Capital Markets reiterated an “outperform” rating and issued a $48.00 target price (up previously from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th. Finally, Sanford C. Bernstein upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, December 20th.

Genmab A/S Price Performance

Shares of GMAB stock opened at $23.33 on Wednesday. Genmab A/S has a one year low of $18.64 and a one year high of $31.88. The firm has a 50-day moving average of $21.08 and a 200-day moving average of $22.70. The company has a market cap of $15.44 billion, a P/E ratio of 13.41, a P/E/G ratio of 2.65 and a beta of 0.96.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings data on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. As a group, research analysts expect that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Genmab A/S

Several hedge funds have recently bought and sold shares of the stock. Deep Track Capital LP bought a new stake in Genmab A/S during the fourth quarter valued at approximately $41,740,000. Renaissance Technologies LLC lifted its holdings in shares of Genmab A/S by 7.8% in the 4th quarter. Renaissance Technologies LLC now owns 1,926,150 shares of the company’s stock worth $40,199,000 after acquiring an additional 139,722 shares during the last quarter. Two Sigma Investments LP lifted its holdings in shares of Genmab A/S by 122.2% in the 4th quarter. Two Sigma Investments LP now owns 1,706,364 shares of the company’s stock worth $35,612,000 after acquiring an additional 938,455 shares during the last quarter. Two Sigma Advisers LP lifted its holdings in shares of Genmab A/S by 168.8% in the 4th quarter. Two Sigma Advisers LP now owns 1,653,500 shares of the company’s stock worth $34,509,000 after acquiring an additional 1,038,400 shares during the last quarter. Finally, First Trust Advisors LP lifted its holdings in shares of Genmab A/S by 18.0% in the 4th quarter. First Trust Advisors LP now owns 1,644,288 shares of the company’s stock worth $34,316,000 after acquiring an additional 251,241 shares during the last quarter. 7.07% of the stock is currently owned by institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.